Month: May 2025

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW. NEW EUR 2025/2027 NOTES Closed – End Investment Company Intended for Informed Investors UAB “Atsinaujinančios energetikos investicijos” (the “Company”) is launching its public offering of EUR 2025/2027 Notes (ISIN LT0000134439, the “Notes”). The Notes are being issued under the EUR 100 million Green Bond Programme. The base prospectus of the programme (the “Prospectus”) was approved by the Bank of Lithuania on 27 May 2025.According to the final terms of the first tranche, dated 27 May 2025 (attached), the Company is planning...

Strategic move into digital infrastructure includes long-term Bitcoin accumulation, potential AI data center expansion and future NASDAQ spin-out TORONTO, May 27, 2025 (GLOBE NEWSWIRE) — Blockmate Ventures Inc. (TSX.V: MATE) (OTCQB: MATEF) (FSE: 8MH) (“Blockmate” or the “Company”), a Blockchain & Web3 venture builder focused on digital asset infrastructure, has launched its wholly owned subsidiary Blockmate Mining, a dedicated Bitcoin mining business with ambitions to become a major player in the North American market. The new entity will pursue a long-term “mine-and-hold” strategy, accumulating Bitcoin on its balance sheet as it scales operations. Blockmate Mining has secured a site in Wyoming, USA, adjacent to a major power substation, with the potential to support up to 200 megawatts (MW) of mining capacity. The Company...

MIAMI, May 27, 2025 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (“SKYX” or the “Company”), a highly disruptive smart home platform technology company with over 97 issued and pending patents globally and a growing portfolio of over 60 lighting and home décor websites, with a mission to make homes and buildings become smart, safe, and advanced as the new standard, today announced that it is set to be added to the Russell 2000® and the broad-market Russell 3000® Index following the 2025 annual reconstitution of the Russell indexes, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. SKYX’s inclusion will become effective after the U.S. market opens on June 27, 2025. Annual Russell index reconstitution ranks the Russell 2000® Index and the 3,000 largest U.S. public companies by total market...

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE IN THIS STOCK EXCHANGE RELEASE BELOW. On 16 May 2025 an extraordinary general meeting of shareholders of UAB “Atsinaujinančios energetikos investicijos”, the closed-end investment company intended for informed investors (hereinafter, the “Company”) approved up to EUR 100,000,000 nominal value Unsecured Fixed Rate Note Programme (hereinafter, the “Notes”). The Company has drafted the base prospectus for the Notes issued under the programme to be introduced to trading on the regulated market AB Nasdaq Vilnius Bond list (hereinafter, the “Prospectus”), which was...

WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June. Jefferies Global Healthcare Conference 2025, New YorkFireside ChatJune 4, 2025, at 7:35 am ET Oppenheimer Innovators in I&I Summit, New YorkPanelist: “Dermatology: AA, HS, PSO”June 25, 2025, at 10am ET Live webcasts and replays, when available, can be found under “News / Events” in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company focused on...